Last reviewed · How we verify

Cubicin — Competitive Intelligence Brief

Cubicin (Daptomycin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: lipopeptide antibacterial. Area: Metabolic.

marketed lipopeptide antibacterial Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Cubicin (Daptomycin) — Baxter. Daptomycin is an antibacterial drug with lipopeptide structure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cubicin TARGET Daptomycin Baxter marketed lipopeptide antibacterial 2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (lipopeptide antibacterial class)

  1. Baxter · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cubicin — Competitive Intelligence Brief. https://druglandscape.com/ci/daptomycin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: